内容紹介
History of and Novel Developments in Cancer Immunotherapy―Introduction to the Special Issue
Summary
Over the last 50 years, development in the field of cancer immunotherapy has been fluctuating, ranging from exciting expectations to disappointing clinical outcomes. Now, the time has come again, for cancer immunotherapy. Since 2010, new immunotherapeutics have been approved one after another in the United States of America and other countries. Thus, immunotherapy has definitely been recognized as the fourth therapy for cancer after surgery, radiotherapy, and chemotherapy. Under this establishment, there has been progress not only in the fundamental understanding of the immune system but also in the design of scientific clinical trials, in which delayed-type tumor responses and survival benefits with less tumor shrinkage are used as indicators. The next 3 papers provide exciting insights on novel cancer immunotherapy as an innovative treatment modality for cancer.
要旨
過去半世紀,がん免疫療法は期待と衰退の歴史を繰り返してきたが,今また世界的に注目されている。2010年以降,米国を筆頭に次々と新規免疫療法が承認され,第四のがん治療として認知された。この背景には,基盤的な免疫学の理解と,その科学的根拠に基づく探索的臨床試験の展開および免疫療法ならではの検証的臨床試験デザイン,すなわち腫瘍縮小にとらわれない生命予後を指標とした臨床評価,これらの進歩があった。本特集を一読いただき,がん免疫療法の進歩と近未来に迫る大きな潮流,がん治療の革新の息吹を感じていただきたい。
目次
Summary
Over the last 50 years, development in the field of cancer immunotherapy has been fluctuating, ranging from exciting expectations to disappointing clinical outcomes. Now, the time has come again, for cancer immunotherapy. Since 2010, new immunotherapeutics have been approved one after another in the United States of America and other countries. Thus, immunotherapy has definitely been recognized as the fourth therapy for cancer after surgery, radiotherapy, and chemotherapy. Under this establishment, there has been progress not only in the fundamental understanding of the immune system but also in the design of scientific clinical trials, in which delayed-type tumor responses and survival benefits with less tumor shrinkage are used as indicators. The next 3 papers provide exciting insights on novel cancer immunotherapy as an innovative treatment modality for cancer.
要旨
過去半世紀,がん免疫療法は期待と衰退の歴史を繰り返してきたが,今また世界的に注目されている。2010年以降,米国を筆頭に次々と新規免疫療法が承認され,第四のがん治療として認知された。この背景には,基盤的な免疫学の理解と,その科学的根拠に基づく探索的臨床試験の展開および免疫療法ならではの検証的臨床試験デザイン,すなわち腫瘍縮小にとらわれない生命予後を指標とした臨床評価,これらの進歩があった。本特集を一読いただき,がん免疫療法の進歩と近未来に迫る大きな潮流,がん治療の革新の息吹を感じていただきたい。